Table 1.

General characteristics of patients

PatientsAge, ySexDiseaseHSCT or CAR T cellPrevious contact with PC teamReferred byHematology follow-upSurvival after first consultation, dOncologic treatmentNumber of consultationsReferrals to emergency departmentNumber of hospitalizations and length of stay, dTime between consultation and hospitalization, dBlood transfusionsPlace of death
P1 78 AML No No Hematologist Yes 86 No 2 (7 + 13) 43 PC department 
P2 73 Diffuse B lymphoma No No Hematologist No 112 Yes, radiotherapy 1 (5) 107 Medical department 
P3 80 Myeloma No No Hematologist Yes No 1 (7) Medical department 
P4 84 AML No No Hematologist No 33 No  Home 
P5 82 Diffuse B lymphoma No Yes PC department No 26 Yes, radiotherapy  Home 
P6 62 Myeloma Yes No Hematologist No 59 No  Home 
P7 79 AML No No Hematologist Yes 97 No  Home 
P8 40 Hodgkin lymphoma Yes No Hematologist Yes 70 Yes, target therapy 1 (1) 69 PC department 
P9 83 MDS No Yes Hematologist Yes 63 No 2 (2 + 5) PC department 
P10 88 Mantle cell lymphoma No No Hematologist No 335  Yes, target therapy  
P11 88 Hodgkin lymphoma No No Hematologist No 24 No 1 (23) PC department 
P12 88 AML No No Hematologist No No 1 (9) PC department 
P13 81 Myeloma No No Hematologist Yes 101 Yes, IV chemotherapy 1 (2) 99 Emergency department 
P14 60 T lymphoma No No Hematologist Yes 186 Yes, oral chemotherapy 1 (25) 166  
P15 80 Mantle cell lymphoma No No Hematologist No 32 Yes, oral chemotherapy 1 (18) 13 PC department 
P16 82 Hodgkin lymphoma No No Hematologist Yes 159 Yes, oral chemotherapy   
P17 85 T lymphoma No No Hematologist Yes 123 No   
P18 92 Burkitt lymphoma No No Hematologist No 109 Yes, targeted therapy  Home 
P19 63 Diffuse B lymphoma Yes No Hematologist No 122 No 1 (12) 98 Home 
P20 52 Diffuse B lymphoma No No Hematologist Yes 109 Yes, targeted therapy   
P21 85 AML No No Hematologist No 14 Yes, oral chemotherapy 1 (10) Medical department 
P22 41 ALL Yes No Hematologist No 28 No 1 (1) 28 PC department 
P23 93 Diffuse B lymphoma No No Hematologist Yes 18 Yes, oral chemotherapy   
PatientsAge, ySexDiseaseHSCT or CAR T cellPrevious contact with PC teamReferred byHematology follow-upSurvival after first consultation, dOncologic treatmentNumber of consultationsReferrals to emergency departmentNumber of hospitalizations and length of stay, dTime between consultation and hospitalization, dBlood transfusionsPlace of death
P1 78 AML No No Hematologist Yes 86 No 2 (7 + 13) 43 PC department 
P2 73 Diffuse B lymphoma No No Hematologist No 112 Yes, radiotherapy 1 (5) 107 Medical department 
P3 80 Myeloma No No Hematologist Yes No 1 (7) Medical department 
P4 84 AML No No Hematologist No 33 No  Home 
P5 82 Diffuse B lymphoma No Yes PC department No 26 Yes, radiotherapy  Home 
P6 62 Myeloma Yes No Hematologist No 59 No  Home 
P7 79 AML No No Hematologist Yes 97 No  Home 
P8 40 Hodgkin lymphoma Yes No Hematologist Yes 70 Yes, target therapy 1 (1) 69 PC department 
P9 83 MDS No Yes Hematologist Yes 63 No 2 (2 + 5) PC department 
P10 88 Mantle cell lymphoma No No Hematologist No 335  Yes, target therapy  
P11 88 Hodgkin lymphoma No No Hematologist No 24 No 1 (23) PC department 
P12 88 AML No No Hematologist No No 1 (9) PC department 
P13 81 Myeloma No No Hematologist Yes 101 Yes, IV chemotherapy 1 (2) 99 Emergency department 
P14 60 T lymphoma No No Hematologist Yes 186 Yes, oral chemotherapy 1 (25) 166  
P15 80 Mantle cell lymphoma No No Hematologist No 32 Yes, oral chemotherapy 1 (18) 13 PC department 
P16 82 Hodgkin lymphoma No No Hematologist Yes 159 Yes, oral chemotherapy   
P17 85 T lymphoma No No Hematologist Yes 123 No   
P18 92 Burkitt lymphoma No No Hematologist No 109 Yes, targeted therapy  Home 
P19 63 Diffuse B lymphoma Yes No Hematologist No 122 No 1 (12) 98 Home 
P20 52 Diffuse B lymphoma No No Hematologist Yes 109 Yes, targeted therapy   
P21 85 AML No No Hematologist No 14 Yes, oral chemotherapy 1 (10) Medical department 
P22 41 ALL Yes No Hematologist No 28 No 1 (1) 28 PC department 
P23 93 Diffuse B lymphoma No No Hematologist Yes 18 Yes, oral chemotherapy   

ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; F, female; HSCT, allogeneic stem cell transplantation; M, male; MDS, myelodysplastic syndrome.

or Create an Account

Close Modal
Close Modal